BioSpace News Archive

Transfusion transmitted infections are still likely to occur despite various proactive measures taken for blood safety such as stringent donor screening, introduction of new exclusion criteria post-donation tracking, and transfusion haemovigilance.

The rise in beauty standards worldwide is likely to add as a notable factor boosting the global liposuction surgery devices market during the forecast period, 2020 to 2030.

Erythropoietic protoporphyria refers to a porphyria that is a rare disease type related to a weakened activity of ferrocheletase, which is key enzyme in heme production.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per insights by Fact.MR, the global market for multiphoton microscopy is expected expand at a 5% CAGR over the forecast period 2021-2031, on the back of increasing adoption of multiphoton microscopy in the cancer research centres.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference at approximately 3:45 PM EST.

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will today provide an update on its Vision 3x3 and planned 2022 key milestones at the 40th Annual J.P. Morgan Healthcare Conference.

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2021.

TrialSpark announced today the formation of High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA, Darmstadt, Germany.

Akura Medical, Inc., a Shifamed portfolio company, announced the closing of its $25M Series A1 financing, which will be used to support the development of its next-generation thrombectomy device.

Vaxiion Therapeutics, the industry leader in bacterial-minicell based cancer immunotherapies, today announced the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application (IND) for VAX014 for investigational use in the intralesional treatment of solid tumors refractory to standard treatment options.